RenovoRx case series reports tumor responses in two advanced pancreatic cancer patients
AI Summary- RenovoRx announced a peer-reviewed case series involving two locally advanced pancreatic cancer patients.
- Both patients received local intra-arterial gemcitabine through RenovoCath and showed treatment responses.
- RenovoRx completed TIGeR-PaC enrollment in August 2026, with topline data expected in late 2027.